2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1064

Identification of a Panel of Circulating Proteins Associated to Synovial Pathotypes in Early Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1077

Identification of Biomarkers Involved in the Resolution Phase of Inflammation: Specialized Pro-Resolving Mediator Receptors Expression in Rheumatoid Arthritis

Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1488

Identification of Joint Locations That Are Poor Prognostic in an Early Seropositive Erosive RA Cohort

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1293

Identification of New and Rare Variants in ABCG2, SLC22A1 and ALDH16A1 Genes in Crystal-Proven Early-Onset Gout

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1048

Identification of Novel Molecules with Senolytic and Autophagy Activity As Osteoarthritis Therapeutics

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1118

Identification of Transcriptional Regulatory Networks in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 1095

IFN Gene Expression Correlates with Frequency of Circulating Switched Memory B-Cells in Patients with Incomplete Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1775

IgG4-Related Disease, Clinical Series on Chilean Patients

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 985

IL-6 and TNF-a Cooperate to Modulate Cell Cycle of RA-FLS Via Cyclin Dependent Kinase 6

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1685

IL2 Decrease Is Associated to ANTI-DNA Positivity in Systemic LUPUS Erythematous Patients

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1092

Immune Complex-Driven Neutrophil Activation and BAFF Production Promote B Cell Activation and Autoantibody Production in Human SLE

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1289

Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1187

Impact of a Nurse-Led Program of Patient Self-Assessment and Self-Management Axial Spondyloarthritis: Results of a Prospective, Multicentre, Randomized, Controlled Trial

Health Services Research Poster II – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 1601

Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis: Results from a Cross-Sectional Observational Study in the United States

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1514

Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].